

Sacituzumab govitecan TROPiCS-02

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Delayed deterioration claimed, does not meet ESMO-MCBS QoL standards



**Serious and disabling adverse effects**




**Other adjustments**



Sacituzumab govitecan TROPiCS-02

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Therapeutic Indication: Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting

Experimental Arm: Sacituzumab govitecan

Control Arm: Physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine)



